A Rare Case of Three Distinct Epstein-Barr Virus Associated Lymphoproliferative Disorders Over Sixteen Years of Human Immunodeficiency Virus Infection

Epstein Barr virus (EBV) is well known to cause different types of malignancies. In immunocompromised patients, such as those infected with human immunodeficiency virus (HIV), there is a higher likelihood of EBV related malignant transformation. Diagnosis of EBV related malignancies may be difficult...

Full description

Saved in:
Bibliographic Details
Published inHematology reports Vol. 9; no. 2; p. 6992
Main Authors Ahmed, Hamdy M A, Khan, Abrar, Lam, Weyman, Abohamad, Samar, Phatak, Pradyumna
Format Journal Article
LanguageEnglish
Italian
Published Italy MDPI AG 01.06.2017
PAGEPress Scientific Publications, Pavia, Italy
PAGEPress Publications, Pavia, Italy
Subjects
Case Report
EBV, HIV, lymphoproliferative disorders, lymphoma
Epstein-Barr virus
HIV
Human immunodeficiency virus
Immunocompromised hosts
Immunoproliferative diseases
Lymphocytes
Malignancy
Patients
lymphoproliferative disorders
EBV
HIV
lymphoma
Online AccessGet full text

Cover

More Information
Summary:Epstein Barr virus (EBV) is well known to cause different types of malignancies. In immunocompromised patients, such as those infected with human immunodeficiency virus (HIV), there is a higher likelihood of EBV related malignant transformation. Diagnosis of EBV related malignancies may be difficult and sometimes requires clinical and pathological correlation. It is very rare to have more than one type of EBV related malignancy in a single patient. Until now, there are no specific guidelines for treatment of EBV related malignancies and lymphoproliferative disorders (LPD). We present a patient who developed three different types of EBV related LPD during a sixteen-year course of HIV infection.
Bibliography:Contributions: the authors contributed equally.
Conference presentation: this work was done in Rochester General Hospital, Internal Medicine Department. The abstract of this case was presented as poster in the 2016 ASH meeting of Hematologic Malignancies, Chicago, IL, USA.
ISSN:2038-8322
2038-8330
2038-8330
DOI:10.4081/hr.2017.6992